Journals Pub

International Journal of
Nanobiotechnology

ISSN: 2456-0111
Volume 11, Issue 1, 2025
January–June
DOI (Journal): 10.37628/IJN

https://journalspub.com/journal/ijnb

Review IJN

Originative Approaches in Powder Formulation for Enhanced Therapeutic Efficacy

Mohd. Wasiullah[1], Piyush Yadav[2], Shashikant Maury[3,*], Mukul Yadav[4]

Abstract

Powder formulation is a cornerstone in the pharmaceutical industry, playing a vital role in improving drug efficacy and ensuring optimal therapeutic outcomes. However, traditional formulation methods often face significant challenges, such as poor solubility and low bioavailability, which can limit the effectiveness of many drugs. To address these issues, innovative strategies have emerged, including amorphous solid dispersions (ASDs), nanotechnology, and advanced manufacturing techniques like spray drying and hot melt etrusion. ASDs are particularly promising for enhancing bioavailability, as they help convert poorly soluble drugs into more soluble and absorbable forms. Despite their potential, challenges like long-term stability and large-scale production remain significant hurdles. Nanotechnology further revolutionizes drug delivery, with Solid Lipid Nanoparticles (SLNs) demonstrating exceptional biocompatibility and the capacity for controlled release, making them valuable for targeted therapies. Techniques like spray drying and hot melt extrusion allow for precise formulation, improving drug stability and performance. The review underscores the critical need for ongoing research and innovation to refine these approaches, optimize formulations, and enhance patient outcomes.

Keywords: Freeze Drying, hot melt extrusion nanoparticle, nanocrystallization, spray drying

INTRODUCTION

Powder formulation plays a crucial role in the development of pharmaceutical products, particularly for enhancing the therapeutic effect of drugs. Traditional powder formulations often face challenges, such as poor solubility, low bioavailability, and limited drug stability. To address these issues, innovative approaches have been developed to improve the performance and efficacy of powdered drugs. In recent years, various techniques have emerged to optimize powder properties, including particle size reduction, co–crystallization, and the use of excipients to enhance solubility and stability. These methods aim to improve the drug's absorption, distribution, and overall therapeutic impact [1]. This review focuses on the originative approaches in powder formulation that contribute to enhancing therapeutic outcomes. It will explore key strategies, such as solid dispersion, nanotechnology-based formulations, and other advanced methods that have been successfully applied to boost the efficacy of drugs in powder form. Understanding these approaches is vital for the continuous improvement of pharmaceutical products and patient care. With the increasing number of poorly water-soluble drug candidates, the need for advanced formulation technologies and product development has become more critical. Among the various strategies, amorphous solid dispersions (ASDs) are gaining significant attention due to their improved dissolution characteristics. ASDs can substantially enhance both the dissolution rate and extent of

***Author for Correspondence**
Shashikant Maury
E-mail: skmaurya0008@gmail.com

[1]Principal, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India.
[2]Academic Head, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India.
[3]Principal Department of Pharmacy, Prasad Polytechnic, Jaunpur, Uttar Pradesh, India.
[4]Scholar, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India.

Received Date: December 14, 2024
Accepted Date: December 20, 2024
Published Date:

Citation: Mohd. Wasiullah, Piyush Yadav, Shashikant Maury, Mukul Yadav. Originative Approaches in Powder Formulation for Enhanced Therapeutic Efficacy. International Journal of Nanobiotechnology. 2025; 11(1): 1–10p.

drugs, even though the thermodynamic solubility of active pharmaceutical ingredients (APIs) remains largely unchanged [2]. This improvement boosts supersaturation, which drives passive membrane transport and leads to increased bioavailability. However, the challenge of creating stable ASD forms and scaling up production technologies presents significant hurdles, making it difficult to bring ASD-based products to market.

ASD technologies are now playing a crucial role in continuous manufacturing. However, for ASD production to seamlessly fit into continuous processes, certain foundational steps need to be established. A deeper understanding of the integration between ASD technologies and continuous manufacturing is therefore essential. The initial stages of continuous ASD formulation manufacturing typically pose few challenges, as methods like spray-drying and hot-melt extrusion (HME) are already continuous processes [3]. However, issues often arise postproduction due to poor flow properties of ASD powders, which can affect feeding performance and lead to variations in drug content in final products, such as tablets or capsules. Precise control of mass flow rates during continuous manufacturing becomes vital, particularly for powders with poor flowability. Improving the flowability of ASDs is crucial for ensuring content uniformity in continuous manufacturing. Granulation is one common method to enhance flow properties, but ASDs are sensitive to mechanical stress, high temperatures, and moisture, which can trigger phase separation or crystallization of the API. Alternatively, using specific excipients to improve flow properties is another approach, but careful selection is required to avoid incompatibilities with the API. Recent studies have highlighted the importance of advanced feeding systems and in-line monitoring and control during continuous processes [4]. Understanding the relationship between powder flow properties, feeder performance, and critical quality attributes is key to optimizing continuous manufacturing of ASD-based formulations. Given the growing importance of ASDs and continuous technologies in the pharmaceutical industry, this review aims to compile the latest research and address the challenges associated with these two cutting-edge trends. The paper will cover ASD preparation methods, the impact of flow properties, feeder performance, and the analytical techniques used to monitor and control these processes [5].

BACKGROUND

Powder formulations play a significant role across multiple industries, including pharmaceuticals, cosmetics, and food production, due to their flexibility, ease of preparation, and stability. They are commonly used for delivering active ingredients, especially in the pharmaceutical field, where they are integral to a wide range of drug delivery systems, such as oral and inhalable treatments [6]. Key factors like the choice of additives, particle size, and manufacturing processes greatly affect the performance and stability of these formulations. Recent advances in formulation techniques and a deeper understanding of material characteristics have led to improvements in the design and efficiency of powder-based products. However, challenges like poor flowability, solubility issues, and achieving uniformity continue to pose difficulties. Continued research is needed to address these obstacles and improve the overall quality and effectiveness of powder formulations. This review aims to examine the historical background, ongoing challenges, and recent innovations in powder formulation, with a focus on factors that contribute to their success across different sectors [6].

LIMITATIONS OF TRADITIONAL POWDER FORMULATIONS

Traditional powder formulations have been extensively utilized in industries like pharmaceuticals, cosmetics, and food due to their relatively low production costs and stable shelf life. Despite these benefits, several challenges limit the performance of these formulations. Key issues include poor flow characteristics, inconsistent particle size distribution, and limited bioavailability, all of which can hinder the overall effectiveness of powder products [7]. Furthermore, active ingredients in powder form often degrade when exposed to environmental factors, such as moisture, heat, and light. Additionally, traditional manufacturing techniques often lack the precision necessary to maintain batch-to-batch consistency, leading to product quality variations. These limitations have driven the need for newer technologies aimed at improving formulation methods, enhancing stability, and increasing the effectiveness of powder-based products. Recent innovations, such as spray drying and nano-formulation, have shown potential in addressing these obstacles [8].

NEED FOR INNOVATIVE APPROACHES

The increasing demand for efficient and adaptable powder formulations across various sectors – such as pharmaceuticals, cosmetics, and food – underscores the necessity for innovative strategies to address current challenges. While traditional powder formulations are favoured for their cost efficiency and straightforward production processes, they often encounter critical issues, including poor flow characteristics, lack of uniformity, and stability concerns. These problems can result in inconsistent product quality and diminished bioavailability, ultimately affecting therapeutic effectiveness. In the pharmaceutical industry, many powdered drugs exhibit low solubility and limited absorption, which can impede their effectiveness in clinical applications [9]. Furthermore, conventional manufacturing techniques frequently fall short in delivering precise control over particle size and distribution, leading to inconsistencies across different batches. As a result, there is a growing interest in exploring innovative formulation methods, such as advanced processing techniques, nanotechnology, and the incorporation of novel excipients to improve product performance. Recent advancements, including the use of 3D printing and microencapsulation, have demonstrated potential in enhancing the delivery and efficacy of powder formulations. These innovative approaches not only tackle the limitations of traditional methods but also provide customized solutions for specific needs. This review will examine the critical need for innovative strategies in powder formulation and discuss the latest advancements that are transforming this field [10].

NANOPARTICLE-BASED POWDERS

Nanoencapsulation

One of the key steps in formulating nano-encapsulation is the careful selection and fabrication of suitable wall materials. In creating nano-capsules, the chosen food components and wall materials play a crucial role. It is essential to follow safety measures during the preparation process: the coating around the food components must be properly applied, ensuring there is no leakage. The selection of encapsulation materials and techniques should adhere to established guidelines. When choosing coating materials, it is important to consider a wide range of synthetic and natural polymers, as this choice depends on the desired characteristics of the final product [11]. The chemical composition of the wall material significantly influences the functional properties of the nano-capsule. Ideally, the coating materials should exhibit good workability and favourable rheological properties at higher concentrations during encapsulation. They must effectively support the dispersion or emulsification of active ingredients and stabilize the emulsion during synthesis. During long-term storage and processing, the materials should remain non-reactive with the active ingredients. Additionally, the coating should effectively encapsulate and protect the active components over time. It is also important that the material can completely release any solvents or other substances used in the encapsulation process under drying or dysventilation conditions. The coating must provide adequate protection for the active ingredient against environmental factors, such as heat, humidity, oxygen, and light. Finally, the materials used should be inexpensive and food-grade to avoid regulatory complications [12].

Foods are often enhanced with natural bioactive ingredients that can provide functional and health-promoting benefits beyond their basic nutritional value. Many of these natural bioactive compounds are sensitive to processing and environmental conditions, so improving their stability is crucial [13]. Nano-encapsulation through nanospray drying enables the production of nanoparticles that are more stable, bioavailable, and capable of precise targeting and controlled release. Recent research on nano-encapsulation with nanospray dryers has led to the development of systems for encapsulating various active ingredients in functional foods, including polyphenols, curcumin, quercetin, resveratrol, and epigallocatechin-3-gallate (Figure 1).

Nanocrystallization

Nanocrystals (NCs) are tiny crystalline forms of drugs, measuring less than 1 am in size. These NCs consist entirely of the active drug substance, with no additional matrix materials. Poorly soluble drugs often face significant challenges in biopharmaceutical delivery, including low bioavailability after oral

intake, inadequate skin penetration, the need for large injection volumes for intravenous (IV) administration, and undesirable side effects from traditional IV formulations [14]. To enhance the stability of these pure drug crystals, surfactants or polymers can be utilized. Typically, NCs are formulated as aqueous dispersions (nanosuspensions) that require additional solvent removal to create re-dispersible powders. Since around 2000, these formulations have rapidly gained market availability. Except for one product, all currently available formulations are solid dosage forms like tablets or capsules, with Megace ES being the only liquid suspension on the market. Chemically unstable drugs can benefit from nanocrystalization, which allows for their stabilization in NC form. For example, paclitaxel has been formulated as a nanosuspension to protect it from degradation [15]. Today, it's feasible to prepare and analyse NCs from a variety of substances, including metals and semiconductors. NCs in solution behave like traditional colloids and can be either charge-stabilized or sterically stabilized. Nanosuspensions can be converted into dry powders using techniques like granulation and freeze-drying [16]. These dry powders can then be further processed into tablets or capsules, which have shown promising results in both in vitro and in vivo studies. Their potential applications span novel drug delivery systems, targeted drug delivery, diagnostics, and tissue engineering (Figure 2).



Figure 1. Nanoencapsulation.



Figure 2. Nanocrystallization.

Amorphous Solid Dispersion (ASDs)

Spray Drying

Nano spray drying is particularly effective for forming NPs, especially when using a smaller mesh aperture size of 4.0 micrometers and a highly diluted feed solution (~0.1% w/w). This method has been utilized to produce NP-based dry powders for inhalation purposes. For instance, employed β-galactosidase as a model protein to investigate the creation of respirable protein powders stabilized with trehalose using the Nano Spray Dryer B-90. They evaluated the impact of factors, such as inlet temperature, spray cap size, and ethanol concentration in the spray solution on both process performance and particle quality. It was found that inlet temperature affected enzyme activity, but this effect varied with the size of the spray cap. Higher product recovery was linked to lower inlet temperatures, increased ethanol content, and smaller cap sizes. Additionally, the protein demonstrated greater storage stability when spraydried without ethanol and with a larger spray cap size [17].

In a different study, produced inhalable powders of the anti-tubercular drug capreomycin sulphate using the Nano Spray Dryer B-90. They optimized the process through experimental design, focusing on membrane pore size, inlet temperature, and solution concentration [18]. The optimized capreomycin particles, combined with lactose, showed approximately a 27% respirable fraction in tests conducted using a TSI device (Figure 3).



Figure 3. Spray Dying.

FREEZE DRYING

A laboratory-scale freeze-dryer, the LyoStar II (SP Scientific Inc., USA), was utilized for the freeze-drying process. Pre-frozen samples were placed onto shelves of the freeze-dryer, which were cooled to –50°C immediately after freezing with liquid nitrogen (LN2). The chamber pressure was set and maintained at 20mTorr throughout the entire freeze-drying cycle to accommodate the low vapor pressure of dimethyl sulfoxide (DMSO). The freeze-drying commenced at a temperature of –50°C. During the drying process, the chamber pressure was monitored using Pirani and capacitance manometer vacuum sensors [19]. The capacitance manometer provides readings that are not affected by gas composition, while the Pirani reading varies based on the gas composition. Typically, during sublimation of the frozen solvent, the Pirani reading is slightly higher than that of the capacitance manometer. Once sublimation is complete, the readings from both sensors equalize.

When the Pirani and capacitance manometer readings matched at –50°C, the temperature was gradually increased to –30°C at a rate of 0.1°C per minute. Throughout the remaining drying phase, the difference between the readings from the two sensors was monitored, and the shelf temperature was raised in increments of 2.5°C whenever equal pressure readings were achieved. This method aimed to maintain the drying temperature as low as possible to prevent melt back, collapse, and recrystallization of the samples. The final temperature for freeze-drying was set at –25°C, where drying continued for

72 hours [20]. After the freeze-drying process was complete, the vacuum was released by backfilling with dry nitrogen, and the vials were sealed before finishing the drying process and removing them from the freeze-dryer. Due to the nature of this freeze-drying cycle, where temperature adjustments were based on the pressure differences between the sensors, the transition between primary and secondary drying could not be specifically determined (Figure 4).



Figure 4. Freeze Drying.

HOT MELT EXTRUSION

Hot melt extrusion (HME) is a widely recognized technique in the plastics industry for creating products with consistent shape and density, with its origins tracing back to the 1930s (1). In recent years, HME has found applications in the healthcare sector, where it is utilized to produce medical devices, amorphous solid dispersions (ASDs) that improve the bioavailability of poorly soluble active pharmaceutical ingredients (APIs), targeted drug delivery systems, implants, bio adhesive films, and products designed to mask taste [21]. The scale-up of the hot melt extrusion (HME) process was performed using 16-mm and 18-mm extruders (Leistritz, Somerville, NJ), both featuring intermeshing co-rotating twin screws. The 16-mm nanoextruder was equipped with four heating zones and a volumetric dosing feeder that introduced the physical blend into the extruder from the bottom. During the extrusion process, the first three zones were maintained at 180°C, while the fourth zone, located near the die, was set to 165°C. The screw design included various conveying elements and kneading elements at angles of 30° and 60° to aid in the dissolution of compound X within the molten polymer [22]. The molten mixture was then forced through a 2-mm round die opening to produce round extrudates. Throughout the extrusion, parameters, such as melt temperature, melt pressure, and torque were recorded.

The 18-mm extruder featured seven heating zones, co-rotating twin screws, and a die plate with a 3-mm round die opening. All heating zones were maintained at 180°C during the extrusion process. The screw profile comprised various conveying elements along with kneading elements at angles of 30°, 60°, and 90° to provide sufficient mechanical shear energy for the formation of amorphous solid dispersions (ASD) (Figure 5).



Figure 5. Hot Melt Extrusion.

OTHER ORIGINATIVE APPROACHES

Powdered Liquid Formulations

- *Spray Drying:* Spray drying is a method for converting liquid formulations into powders, offering benefits, such as fast drying, consistent particle size, and versatility in industries like pharmaceuticals and food. It minimizes thermal degradation risks and enhances solubility.
- *Freeze Drying (Lyophilization):* Spray drying is a method for converting liquid formulations into powders, offering benefits, such as fast drying, consistent particle size, and versatility in industries like pharmaceuticals and food. It minimizes thermal degradation risks and enhances solubility.
- *Coacervation:* Coacervation is a technique that separates a liquid phase into two immiscible phases, creating microcapsules around active ingredients, providing protection and controlled release.
- *Extrusion:* Extrusion is a process that involves forming a solid product from a liquid formulation, ensuring uniformity and allowing for customization in the final powder [23].

3D PRINTING-BASED POWDERS

Powder-Based 3D Printing Techniques

Several techniques are used in powder-based 3D printing, each with its unique processes and materials:

- *Selective Laser Sintering (SLS):* SLS is a process that uses a laser to fuse powdered materials, such as polymers or metals, creating intricate designs and internal structures. It offers advantages, such as compatibility with various materials like nylon, TPU, and metals, allowing for a wide range of designs.
- *Direct Metal Laser Sintering (DMLS):* DMLS is a high-powered laser-based process that melts and fuses metal particles to create strong, dense components, offering high strength and rapid prototyping for functional applications, thereby accelerating the design process for metal components.
- *Binder Jetting:* Binder jetting is a process where a liquid binder is selectively deposited onto a powder layer, bonding particles together. It's faster than traditional sintering and can produce larger parts with lower material waste. It's suitable for ceramics and metals [24].

CHALLENGES AND FUTURE DIRECTIONS

Scalability and Manufacturing Current Challenges

- *Lab to Production Transition:* Powder formulation faces challenges in transitioning from small-scale lab experiments to large-scale manufacturing, as well as variability in particle size and flow characteristics, which are not easily addressed in controlled lab conditions.
- *Manufacturing Methods:* Traditional manufacturing processes may not be perfect for every powder formulation, especially those requiring specific particle traits or uniformity, and the lack of consistency during scaling can be complicated by non-standardized production protocols.
- *Cost Issues:* Large-scale production can pose significant financial challenges for manufacturers, particularly smaller firms or startups, due to the high costs associated with equipment, materials, and quality assurance.

FUTURE DIRECTIONS

- *Automation and Continuous Processes:* Investing in automated systems and continuous manufacturing techniques can boost efficiency, reduce costs, and improve product quality by enabling real-time monitoring and parameter adjustments.
- *Collaboration Among Stakeholders:* Strengthening collaborations between pharmaceutical companies, equipment manufacturers, and research institutions can foster innovation in scalable manufacturing techniques, potentially leading to the development of new formulations and processes.
- *Advanced Characterization Methods:* Advanced techniques like particle size analysis, flowability assessments, and moisture content evaluations can optimize formulations and production processes before scaling.

STABILITY AND STORAGE

Current Challenges

- *Risk of Degradation:* Powder formulations are susceptible to degradation due to environmental factors like humidity, temperature changes, and light exposure, potentially compromising drug effectiveness and safety.
- *Packaging Limitations:* The current packaging solutions may not adequately protect formulations from environmental conditions, posing challenges in maintaining stability during storage and transport [25].

FUTURE DIRECTIONS

- *Novel Excipients Development:* New excipients for powder formulation stability could extend shelf life, protect active ingredients from degradation, and maintain desired release profiles.
- *Improved Packaging Solutions:* Advanced packaging materials like desiccant sachets, vacuum sealing, and blister packaging are crucial for protecting powder formulations from moisture and light.
- *Standardized Storage Guidelines:* Standardized recommendations for optimal storage conditions like temperature, humidity, and light exposure are crucial for ensuring formulations maintain stability and efficacy over time.

REGULATORY FRAMEWORK

Current Challenges

- *Complex Regulatory Landscape:* The regulatory landscape for powder formulations, particularly inhalable drugs, is complex and regionally varying, leading to lengthy approval processes and uncertainty for manufacturers.
- *Inconsistent Standards:* The potential absence of uniformity in regulatory standards across various nations could potentially hinder market access and compliance.

FUTURE DIRECTIONS

- *Streamlining Approval Processes:* Regulatory agencies can streamline approval pathways for innovative powder formulations, expediting approvals for novel therapies or formulations that meet unmet medical needs for faster market entry.
- *Enhanced Communication:* Enhancing communication between regulatory bodies and pharmaceutical companies can enhance clarity of requirements and expectations, facilitating more efficient submissions and approvals.
- *Risk-Based Regulatory Approaches:* Implementing risk-based frameworks that prioritize regulatory resources based on a product's potential public health impact can foster innovation while maintaining safety and efficacy standards.

CONCLUSIONS

The advancements in powder formulation, particularly in the context of amorphous solid dispersions (ASDs) and nanoparticle-based powders, have significantly enhanced the therapeutic efficacy and stability of pharmaceutical products. Innovative techniques, such as spray drying, freeze drying, and hot melt extrusion have emerged as critical methodologies for overcoming traditional limitations, including poor solubility and bioavailability. The ability to utilize nanoencapsulation and nanocrystallization not only improves the delivery of active pharmaceutical ingredients (APIs) but also facilitates targeted release and better patient outcomes.

Despite these advancements, challenges remain, particularly regarding the scalability and stability of ASDs in continuous manufacturing processes. Ensuring uniform flow properties and content consistency is essential for successful integration into production lines. Moreover, the interplay between formulation methods and continuous processes must be carefully managed to optimize performance.

Continued research and development in this field are crucial for addressing existing limitations and harnessing the full potential of powder formulations. As the pharmaceutical landscape evolves, the integration of innovative formulation technologies will play a pivotal role in meeting the growing demand for effective and adaptable drug delivery systems. By leveraging these advanced methods, the industry can improve patient care and therapeutic outcomes, paving the way for the next generation of pharmaceutical products.

In summary, solid lipid nanoparticles (SLNs) and SLN-based powders represent a significant advancement in drug delivery systems, offering enhanced bioavailability, controlled release, and improved stability. Various preparation methods, including high shear homogenization and spray drying, contribute to the development of these formulations. While challenges, such as scalability, stability, and regulatory complexities exist, future directions focusing on automation, novel excipients, and streamlined regulatory processes can pave the way for more efficient manufacturing and improved patient outcomes. Overall, SLNs and their powdered formulations hold great promise for innovative therapeutic applications.

REFERENCES

1. Agrawal AM, Dudhedia MS, Zimny E. Hot Melt Extrusion: Development of an Amorphous Solid Dispersion for an Insoluble Drug from Mini-scale to Clinical Scale. AAPS Pharm Sci Tech. 2016;17(1):133–47. doi:10.1208/s12249–015–0425–7.
2. Chopde S, Datir R, Deshmukh G, Dhotre A, Patil M. Nanoparticle formation by nanospray drying & its application in nanoencapsulation of food bioactive ingredients. J Agric Food Res. 2020;2:100085. doi:10.1016/j.jafr.2020.100085.
3. Debnath SK, Saisivam S, Debanth M, Omri A. Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide. PLoS One. 2018;13(1): e0190976. doi: 10.1371/journal.pone.0190976.
4. Fitriani L, Haqi A, Zaini E. Preparation and characterization of solid dispersion freeze-dried efavirenz-Polyvinylpyrrolidone K–30. J Adv Pharm Technol Res. 2016;7(3):105–9. doi:10.4103/2231–4040.184592.
5. Joshi K, Chandra A, Jain K, Talegaonkar S. Nanocrystalization: An Emerging Technology to Enhance the Bioavailability of Poorly Soluble Drugs. Pharm Nanotechnol. 2019;7(4):259–78. doi:10.2174/2211738507666190405182524.
6. Liu J, Grohganz H, Löbmann K, Rades T, Hempel NJ. Co–amorphous drug formulations in numbers: Recent advances in co–amorphous drug formulations with focus on co–formability, molar ratio, preparation methods, physical stability, in vitro and in vivo performance, and new formulation strategies. Pharma. 2021;13(3):389. doi:10.3390/pharmaceutics13030389.
7. Luca A. Effect of nanoencapsulation of purified polyphenolic powder on encapsulation efficiency, storage and baking stability [thesis]. Middle East Technical University; 2012.
8. Malamatari M, Charisi A, Malamataris S, Kachrimanis K, Nikolakakis I. Spray drying for the preparation of nanoparticle–based drug formulations as dry powders for inhalation. Processes. 2020;8(7):788. doi:10.3390/pr8070788.
9. Manjunath K, Ready JS, Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol. 2005;27(2):127–44. doi:10.1358/mf.2005.27.2.876286.
10. Santonocito D, Sarpietro MG, Castelli F, Lauro MR, Torrisi C, Russo S. Development of solid lipid nanoparticles as dry powder: characterization and formulation considerations. Mol. 2023;28(4):1545. doi:10.3390/molecules28041545.
11. Shah DS, Moravkar KK, Jha DK, Lonkar V, Amin PD, Chalikwar SS. A concise summary of powder processing methodologies for flow enhancement. Heliyon. 2023;9(6):e16498. doi: 10.1016/j.heliyon. 2023.e16498.
12. Shi Q, Moinuddin SM, Cai T. Advances in coamorphous drug delivery systems. Acta Pharm Sin B. 2019;9(1):19–35. doi: 10.1016/j.apsb.2018.08.002.

13. Szabó E, Galata DL, Vass P, Hirsch E, Csontos I, Marosi G. Continuous formulation approaches of amorphous solid dispersions: Significance of powder flow properties and feeding performance. Pharma. 2019;11(12):654. doi:10.3390/pharmaceutics11120654.
14. Tahir A, Shabir Ahmad R, Imran M, Ahmad MH, Kamran Khan M, Muhammad N. Recent approaches for utilization of food components as nano–encapsulation: A review. Int J Food Prop. 2021;24(1):1074–96. doi:10.1080/10942912.2021.1953067.
15. Valkama E, Haluska O, Lehto VP, Korhonen O, Pajula K. Production and stability of amorphous solid dispersions produced by a Freeze–drying method from DMSO. Int J Pharm. 2021; 606:120902. doi: 10.1016/j.ijpharm.2021.120902.
16. Wang Y, Xu Z, Wu D, Bai J. Current status and prospects of polymer powder 3D printing technologies. Mater. 2020;13(10):2406. doi:10.3390/ma13102406.
17. Yan X, Tong Z, Chen Y, Mo Y, Feng H, Li P. Bioresponsive materials for drug delivery based on carboxymethyl chitosan/poly (γ-glutamic acid) composite microparticles. Mar Drugs. 2017;15(5):127. doi:10.3390/md15050127.
18. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29:278–87.
19. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water–soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. Int J Pharm. 2011;420:1–10.
20. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12:1068–75.
21. Hoppentocht M, Hagedoorn P, Frijlink HW, de Boer AH. Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev. 2014;75:18–31.
22. Bonaccorso A, Pellitteri R, Ruozi B, Puglia C, Santonocito D, Pignatello R, et al. Curcumin loaded polymeric vs. lipid nanoparticles: Antioxidant effect on normal and hypoxic olfactory ensheathing cells. Nanomater. 2021;11(159):1–15.
23. Luo WC, Beringhs AO, Kim R, Zhang W, Patel SM, Bogner RH. Impact of formulation on the quality and stability of freeze-dried nanoparticles. Eur J Pharm Biopharm. 2021;169:256–67.
24. Kour H, Malik AA, Ahmad N, Wani TA, Kaul RK, Bhat A. Nanotechnology—New lifeline for food industry. Crit Rev Food Sci Nutr. 2015;60(20):1–10.
25. Khare AR, Vasisht N. Nanoencapsulation in the food industry: Technology of the future. In: Gaonkar AG, Vasisht N, Khare AR, Sobel R, editors. Microencapsulation in the Food Industry: A Practical Implementation Guide. London: Academic Press; 2014.151–5.

